Success Rate of Embolization for Type II Endoleaks at a Major Tertiary Referral Center by Greer, Garret et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Clinical Research Medical Education Research Forum 2019 
5-2019 
Success Rate of Embolization for Type II Endoleaks at a Major 
Tertiary Referral Center 
Garret Greer 
Henry Ford Health System, garretg@rad.hfh.edu 
Brian Sullivan 
Henry Ford Health System, bsulliv5@hfhs.org 
Ziad Al Adas 
Henry Ford Health System 
Mitchell R Weaver 
Henry Ford Health System, mweaver1@hfhs.org 
David W McVinnie 
Henry Ford Health System, davidm@rad.hfh.edu 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/merf2019clinres 
Recommended Citation 
Greer, Garret; Sullivan, Brian; Al Adas, Ziad; Weaver, Mitchell R; McVinnie, David W; Nypaver, Timothy J; 
Shepard, Alexander D.; and Kabbani, Loay S, "Success Rate of Embolization for Type II Endoleaks at a 
Major Tertiary Referral Center" (2019). Clinical Research. 27. 
https://scholarlycommons.henryford.com/merf2019clinres/27 
This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry 
Ford Health System Scholarly Commons. It has been accepted for inclusion in Clinical Research by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
Garret Greer, Brian Sullivan, Ziad Al Adas, Mitchell R Weaver, David W McVinnie, Timothy J Nypaver, 
Alexander D. Shepard, and Loay S Kabbani 
This poster is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
merf2019clinres/27 
Success Rate for Embolization of 
Type II Endoleaks at a Major Tertiary 
Referral Center​
Garret Greer, DO, Brian P Sullivan, M.Sc, 
Ziad Al-Adas, MD, Mitchell Weaver, MD,
David McVinnie, MD, Timothy Nypaver, 
MD, Alexander Shepard, MD, Loay S. 
Kabbani, MD
Departments of Interventional Radiology and Vascular Surgery
Henry Ford Hospital
Detroit, Michigan
Introduction: 
• Endovascular aneurysm repair (EVAR) has become the 
mainstay in the treatment of abdominal aortic aneurysms 
(AAA).  
• EVAR requires lifetime follow up imaging to monitor for 
signs of endograft migration and development of endoleaks, 
which occur in upwards of 20-25% of EVARs. 
• Type II endoleaks (T2EL) are the most frequent type of 
endoleak and are estimated to account for 40% of all 
endoleaks4, 5. T2EL occur due to retrograde flow into the 
aneurysmal sac through collateral circulation, most 
commonly from the lumbar arteries and the IMA5, 6.  
• Although T2EL may spontaneously resolve, persistent leaks 
associated with increased aneurysm sac growth often require 
intervention1. 
• Several studies have shown that embolization of the 
aneurysm sac and/or collateral vessels can adequately 
disrupt the offending vessels and prevent further sac 
expansion and is an effective treatment for T2EL2-6.
• Primary Objective: 
• Assess our institutional rate of success with first 
embolization of isolated type II endoleaks.
• Secondary Objectives:
• Characterize the population afflicted by type II 
endoleaks.
• Examine the effect(s) of inflow vessel, embolization 
site, and embolization method on success of 
embolization.
• Determine the outcomes of patients who failed initial 
embolization of type II endoleaks. 
Study Objectives:
Above: T2EL via patent IMA.
Above: Same patient 4 years later 
s/p embolization of IMA. Cessation 
of growth after IMA successfully 
occluded.
1. The Institutional Radiology database at our tertiary referral hospital was queried for type II endoleak
during the period 2006-2018. (N=92)
2. A retrospective chart review was then carried out. Only patients who underwent embolization for 
isolated type 2 endoleaks and had follow-up imaging were analyzed (N=92 to N=41). 
3. The follow-up period was defined as the interval between EVAR and most recent aortic imaging 
study.
4. The primary outcome was success of the endoleak repair as determined by cessation of growth of 
the native aneurysm sac (i.e., ≤5mm change in diameter over follow-up period).
5. Data pertaining to patient demographics, location of the endoleak, type of occlusion performed, 
type of endograft used for EVAR, and incidence of aneurysm rupture were collected as secondary 
measures.
Methods
Patient Analysis:
• 41  patients were treated for isolated type II endoleaks and had adequate follow-up for inclusion in 
the study.
• Mean follow-up was 62 months (~5 years).
• Demographics are shown in the table.
•
• Cessation of growth was achieved in 28/41 (68.3%) of the patients after one embolization procedure.  
In 13/41 (31.5%) of patients, growth of the native aneurysm sac continued. 
• Of the patients whose aneurysms continued to grow, 8/13 (61.5%) did not undergo a second 
embolization. The remaining 5/13 (38.5%) underwent a second embolization. 
• In patients who failed embolization, 3/13 (23.1%) were eventually found to have a type 3 endoleak on 
follow-up imaging.
• Smoking history and inflow through lumbar arteries show a closer relationship to failure of 
embolization than do gender, race, site of embolization, or type of embolization.
Results:

• Retrospective observational study.
• Data represents a single institutions experience. 
• As a result of the strict inclusion criteria used for isolated 
type II endoleaks with follow-up, the overall study power 
was low.
Limitations:
• First embolization is successful in halting growth of the 
aneurysm sac in 68.3% of isolated type II endoleaks over a 5 year 
follow-up period.
• A history of smoking and a lumbar inflow vessel may predict a 
more challenging embolization with higher failure rate.
• The site of embolization (intra-vessel, intra-cavity, or both) does 
not significantly impact the rate of success.
• Caution must be taken to make sure the patients do not have an 
occult type I or type III endoleak. 
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